Product Reviews
Categories
- Alternative Medicine
- Cancer
- Acute Promyelocytic Leukemia
- Anal Cancer
- Bladder Cancer
- Breast cancer
- Colorectal cancer
- Endometrial Cancer
- Esophageal Cancer
- Gallbladder cancer
- Gastric Cancer
- Glioblastma
- Head and Neck Cancer
- Liver Cancer
- Lung Cancer
- Lymphoma
- Melanoma
- Nasopharyngeal Cancer
- Non-Hodgkin's Disease
- Ovarian Cancer
- Pancreatic Cancer
- Prostate cancer
- Renal Cancer
- Thyroid Cancer
- Cardiovascular disease
- Central Nervous System
- Constipation
- Diabetes
- Fatty Liver
- Irritable Bowel Syndrome
- Longevity
- Motherhood
- Obesity
- Others
- Psoriasis
- Respiratory Disease
- Rheumatoid Arthritis
Archives
Tag Archives: leucovorin
New Hope for Patients with Advanced Metastatic Colorectal Cancer Patients
Colorectal cancer is the fourth most common cancer in men and women with nearly 500,000 deaths due to colorectal cancer every year. When detected early at localized stage I, the 5-year survival rate can reach 90%. At this stage, surgical … Continue reading →
Posted in Cancer, Colorectal cancer
|
Tagged 5-Fluorouracil, Avastin, bevacizumab, camptosar, Cetuximab, Eloxatin, Erbitux, gastrointestinal stromal tumors, GIST, Gleevec, imatanib, Irinotecan, leucovorin, metastatic colorectal cancer, oxaliplatin, regoragenib, sunitinib, Survival, Sutent
|
Comments Off on New Hope for Patients with Advanced Metastatic Colorectal Cancer Patients
New Treatment for Colorectal Cancer Patients with Liver Metastases
In the past, bevacizumab (Avastin) plus FOLFOX (leucovorin, 5-fluorouracil, and oxaliplatin) is the mainstay treatment for colorectal cancer patients with metastases (Stage IV). Even though the response rate of this regimen is impressive, less than 10% of Stage IV colorectal cancer … Continue reading →
Posted in Cancer, Colorectal cancer
|
Tagged 5-Fluorouracil, Avastin, bevacizumab, chemotherapy, FOLFOX, leucovorin, metastatic colorectal cancer, oxaliplatin, radiofrequency ablation, RFA, Survival
|
Comments Off on New Treatment for Colorectal Cancer Patients with Liver Metastases
